Nuvo Research Inc., of Mississauga, Ontario, reacquired Pennsaid 2 percent (diclofenac sodium) for osteoarthritis of the knee marketing rights to South America, Central America, South Africa and Israel from Paladin Labs Inc., of Montreal, for a noncash consideration.